Literature DB >> 6561954

In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.

S C Aronoff, J D Klinger.   

Abstract

Amikacin, combined with aztreonam, piperacillin, or ticarcillin, synergistically inhibited amikacin-resistant sputum isolates of Pseudomonas aeruginosa and P. cepacia from children with cystic fibrosis. Ticarcillin-amikacin was the least active combination. Aminoglycoside resistance should not preclude the use of beta-lactam-aminoglycoside combinations in the treatment of pulmonary infections in cystic fibrosis.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6561954      PMCID： PMC185490          DOI： 10.1128/AAC.25.2.279

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  In-vitro antibacterial activity of SQ 26,776.

Authors:  R Norrby; K Friberg; S E Holm
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

2.  In-vitro activity of monobactam, SQ 26,776, against Gram-negative bacteria.

Authors:  A Percival; E Thomas; C A Hart; P Karayiannis
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

3.  Antibacterial activity of the monobactam SQ 26,776 against antibiotic resistant enterobacteria, including Serratia spp.

Authors:  D S Reeves; M J Bywater; H A Holt
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

4.  Correlations between methods for measurement of synergy.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1980-09       Impact factor: 5.226

5.  Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilli.

Authors:  D A Strandberg; J H Jorgensen; D J Drutz
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

6.  Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  R K Scribner; M I Marks; A H Weber; M M Tarpay; D F Welch
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

7.  A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis.

Authors:  A C Hyatt; B E Chipps; K M Kumor; E D Mellits; P S Lietman; B J Rosenstein
Journal:  J Pediatr       Date:  1981-08       Impact factor: 4.406
  7 in total
  14 in total

1.  In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis.

Authors:  R C Cohn; M Jacobs; S C Aronoff
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

2.  In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa.

Authors:  M D Lyon; K R Smith; M S Saag; G A Cloud; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

3.  In vitro activity of new antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  A M Horrevorts
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

Review 4.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

5.  Changing susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients with the clinical use of newer antibiotics.

Authors:  J A Bosso; J E Allen; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

6.  In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.

Authors:  J A Bosso; B A Saxon; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

7.  In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia.

Authors:  C Lewin; C Doherty; J Govan
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

8.  In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.

Authors:  J A Bosso; B A Saxon; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 9.  The epidemiology of Pseudomonas cepacia in patients with cystic fibrosis.

Authors:  O C Tablan; W J Martone; W R Jarvis
Journal:  Eur J Epidemiol       Date:  1987-12       Impact factor: 8.082

10.  Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis.

Authors:  G Manno; E Ugolotti; M L Belli; M L Fenu; L Romano; M Cruciani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-01-25       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.